Astrazeneca PLC (NYSE:AZN) posted its quarterly earnings results on Thursday. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.58. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the previous year, the firm posted $1.03 earnings per share. The company’s quarterly revenue was down 2.6% compared to the same quarter last year.

Astrazeneca PLC (NYSE:AZN) opened at 28.95 on Thursday. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The company has a 50 day moving average of $30.91 and a 200-day moving average of $30.87. The stock has a market cap of $73.24 billion, a P/E ratio of 33.09 and a beta of 0.83.

Earnings History for Astrazeneca PLC (NYSE:AZN)

A number of equities analysts have recently commented on AZN shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Cantor Fitzgerald reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Piper Jaffray Cos. began coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They set an “overweight” rating for the company. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, September 28th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $37.56.

Institutional investors have recently made changes to their positions in the company. First Interstate Bank increased its position in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares in the last quarter. Synovus Financial Corp increased its position in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Fifth Third Bancorp increased its position in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Integrated Investment Consultants LLC increased its position in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Astrazeneca PLC by 2,056.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,982 shares of the company’s stock worth $150,000 after buying an additional 4,751 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.